Logo image of IDBA

IDEX BIOMETRICS ASA -ADR (IDBA) Stock Fundamental Analysis

NASDAQ:IDBA - Nasdaq - US45173W1053 - ADR - Currency: USD

4.88  +0.08 (+1.67%)

Premarket: 5.06 +0.18 (+3.69%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IDBA. IDBA was compared to 125 industry peers in the Electronic Equipment, Instruments & Components industry. IDBA may be in some trouble as it scores bad on both profitability and health. IDBA shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IDBA had negative earnings in the past year.
In the past year IDBA has reported a negative cash flow from operations.
IDBA had negative earnings in each of the past 5 years.
In the past 5 years IDBA always reported negative operating cash flow.
IDBA Yearly Net Income VS EBIT VS OCF VS FCFIDBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

IDBA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IDBA Yearly ROA, ROE, ROICIDBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

IDBA has a Gross Margin of 19.87%. This is in the lower half of the industry: IDBA underperforms 61.90% of its industry peers.
IDBA's Gross Margin has been stable in the last couple of years.
IDBA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.63%
GM growth 5Y-0.87%
IDBA Yearly Profit, Operating, Gross MarginsIDBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

IDBA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IDBA has more shares outstanding
The debt/assets ratio for IDBA is higher compared to a year ago.
IDBA Yearly Shares OutstandingIDBA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
IDBA Yearly Total Debt VS Total AssetsIDBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

IDBA has an Altman-Z score of -14.85. This is a bad value and indicates that IDBA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -14.85, IDBA is not doing good in the industry: 96.83% of the companies in the same industry are doing better.
IDBA has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.08, IDBA perfoms like the industry average, outperforming 51.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -14.85
ROIC/WACCN/A
WACC8.22%
IDBA Yearly LT Debt VS Equity VS FCFIDBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M 60M 80M

2.3 Liquidity

IDBA has a Current Ratio of 3.77. This indicates that IDBA is financially healthy and has no problem in meeting its short term obligations.
IDBA has a better Current ratio (3.77) than 70.63% of its industry peers.
A Quick Ratio of 2.57 indicates that IDBA has no problem at all paying its short term obligations.
IDBA has a Quick ratio of 2.57. This is in the better half of the industry: IDBA outperforms 68.25% of its industry peers.
Industry RankSector Rank
Current Ratio 3.77
Quick Ratio 2.57
IDBA Yearly Current Assets VS Current LiabilitesIDBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

IDBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.61%, which is quite good.
IDBA shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.54%.
The Revenue has been growing by 18.32% on average over the past years. This is quite good.
EPS 1Y (TTM)15.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.79%
Revenue 1Y (TTM)35.54%
Revenue growth 3Y113.06%
Revenue growth 5Y18.32%
Sales Q2Q%25.58%

3.2 Future

The Earnings Per Share is expected to grow by 63.26% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 325.45% on average over the next years. This is a very strong growth
EPS Next Y21.12%
EPS Next 2Y-131.83%
EPS Next 3Y63.26%
EPS Next 5YN/A
Revenue Next Year351.61%
Revenue Next 2Y380.54%
Revenue Next 3Y325.45%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDBA Yearly Revenue VS EstimatesIDBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
IDBA Yearly EPS VS EstimatesIDBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IDBA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IDBA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDBA Price Earnings VS Forward Price EarningsIDBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDBA Per share dataIDBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

IDBA's earnings are expected to grow with 63.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-131.83%
EPS Next 3Y63.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IDBA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDEX BIOMETRICS ASA -ADR

NASDAQ:IDBA (8/9/2023, 8:17:19 PM)

Premarket: 5.06 +0.18 (+3.69%)

4.88

+0.08 (+1.67%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)11-09 2023-11-09/bmo
Inst Owners0.06%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap85.63M
Analysts82.86
Price Target5.47 (12.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)97.65%
Min EPS beat(2)97.65%
Max EPS beat(2)97.65%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-92.16%
Min Revenue beat(2)-92.16%
Max Revenue beat(2)-92.16%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.54%
EPS NQ rev (1m)2.29%
EPS NQ rev (3m)-14.9%
EPS NY rev (1m)2.29%
EPS NY rev (3m)-14.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-10.69%
Revenue NY rev (3m)-10.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.71
P/FCF N/A
P/OCF N/A
P/B 5.36
P/tB 6.28
EV/EBITDA N/A
EPS(TTM)-2.07
EYN/A
EPS(NY)-94.82
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0.25
BVpS0.91
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.87%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.63%
GM growth 5Y-0.87%
F-Score1
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.77
Quick Ratio 2.57
Altman-Z -14.85
F-Score1
WACC8.22%
ROIC/WACCN/A
Cap/Depr(3y)15.65%
Cap/Depr(5y)46.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.79%
EPS Next Y21.12%
EPS Next 2Y-131.83%
EPS Next 3Y63.26%
EPS Next 5YN/A
Revenue 1Y (TTM)35.54%
Revenue growth 3Y113.06%
Revenue growth 5Y18.32%
Sales Q2Q%25.58%
Revenue Next Year351.61%
Revenue Next 2Y380.54%
Revenue Next 3Y325.45%
Revenue Next 5YN/A
EBIT growth 1Y3.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.13%
EBIT Next 3Y67.12%
EBIT Next 5YN/A
FCF growth 1Y-29.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.65%
OCF growth 3YN/A
OCF growth 5YN/A